NewLink awarded $25 million contract for Ebola Zaire vaccine

NewLink awarded $25 million contract for Ebola Zaire vaccine

/wp-content/uploads/2022/11/BR_web_311x311.jpeg

BPC Staff | Oct 5, 2016 | 9:10 pm |

<1 min read time

After successful initial trials, Ames-based NewLink Genetics will continue development on the Ebola Zaire vaccine (designated V920), thanks to a $25 million contract from the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services.

Ames Tribune: After successful initial trials, Ames-based NewLink Genetics will continue development on the Ebola Zaire vaccine (designated V920), thanks to a $25 million contract from the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services.

BPC Staff

Email the writer

Trending News

More News

Search